[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100612030":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":30,"centralContacts":34,"locations":44,"responsibleParty":62,"collaborators":26,"id":64,"slug":65,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":68,"acronym":26,"eligibilityCriteria":69,"healthyVolunteers":66,"sex":70,"minAge":71,"maxAge":26,"enrollmentInfo":72,"targetDuration":26,"studyType":75,"phases":76,"briefSummary":78,"conditions":79,"keywords":82,"overallStatus":46,"whyStopped":26,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":88,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"Centre hospitalier de l'Université de Montréal (CHUM)","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Aprepitant","EXPERIMENTAL","Participants will receive a 40 mg capsule of aprepitant, in addition to standard antiemetic prophylaxis.",[13],"Drug: Aprepitant 40mg",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","Participants will receive a 40 mg capsule of placebo, in addition to standard antiemetic prophylaxis",[19],"Drug: Placebo",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Aprepitant 40mg","Just before the patient is taken to the operating room, a single oral capsule of 40 mg of aprepitant will be given to the participant to evaluate the effectiveness of 40 mg of aprepitant in preventing postoperative nausea and vomiting (PONV) in outpatient surgery. The protocol was chosen to determine whether adding aprepitant to a standard multimodal strategy provides a clinically measurable benefit compared to placebo.",[9],null,{"type":22,"name":15,"description":28,"armGroupLabels":29,"otherNames":26},"Just before the patient is taken to the operating room, a single oral capsule of 40 mg of placebo will be given to the participant.",[15],[31],{"name":32,"affiliation":5,"role":33},"Maxim Roy, MD, FRCPC","PRINCIPAL_INVESTIGATOR",[35,40],{"name":32,"role":36,"phone":37,"phoneExt":38,"email":39},"CONTACT","514-890-8000","12132","maxim.roy.med@ssss.gouv.qc.ca",{"name":41,"role":36,"phone":37,"phoneExt":42,"email":43},"Vicky Thiffault, BSN","24542","anesthesie.recherche.chum@ssss.gouv.qc.ca",[45],{"facility":5,"status":46,"city":47,"state":48,"zip":49,"country":50,"countryCode":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":58},"RECRUITING","Montreal","Quebec","H2X 0A9","Canada","CA",{"type":53,"coordinates":54},"Point",[55,56],-73.58781,45.50884,{"lat":56,"lon":55},[59,61],{"name":60,"role":36,"phone":37,"phoneExt":42,"email":43},"Vicky Thiffault, RN",{"name":32,"role":33,"phone":26,"phoneExt":26,"email":26},{"type":63,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100612030","phase-3-adding-aprepitant-to-a-multimodal-strategy-for-the-prevention-of-postoperative-nausea-and-vomiting-in-high-risk-outpatient-surgical-patients-100612030",false,"NCT07248280","Adding Aprepitant to a Multimodal Strategy for the Prevention of Postoperative Nausea and Vomiting in High-risk Outpatient Surgical Patients","Inclusion Criteria:\n\n* 18 years and over, requiring an ambulatory surgery\n* at high risk of post-operative nausea and vomitting defined by at least 3 factors from the Apfel score, calculated just prior to the surgery (female sex; non smoker; previous nausea or vomitting post-op., or motion sickness; expected opioid consumption in postoperative care).\n\nExclusion Criteria:\n\n* Refusal or unable to consent\n* Suspected or documented allergy to aprepitant (emend)\n* Concomitant use of medication interacting via the cytochrome CYP3A4 with aprepitant (pimozide, terfenadine, astemizole, comtadin or cisapride).","ALL","18 Years",{"count":73,"type":74},260,"ESTIMATED","INTERVENTIONAL",[77],"PHASE3","Postoperative nausea and vomiting (PONV) are a frequent and debilitating complications after surgery, affecting up to 80% of patients at high risk in the absence of prophylaxis.\n\nDespite the rigorous application of the recommendations from the American Society of Anesthesiologists (ASA) at CHUM, a recent local study reveals a prevalence of 25% PONV at home after outpatient surgery. However, the therapeutic options at home remain limited.\n\nThis study aims to evaluate if the addition of 40 mg aprepitant to a multimodal strategy for preventing PONV improves clinical outcomes in high-risk patients undergoing outpatient surgery.",[80,81],"Nausea and Vomiting, Postoperative","Prevention",[83,9],"Ambulatory care","2026-02-27",{"date":86,"type":87},"2026-03-03","ACTUAL",{"date":84,"type":87},{"date":90,"type":74},"2027-01-01",{"name":5,"class":6},1]